Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression.

Etzerodt A, Tsalkitzi K, Maniecki M, Damsky W, Delfini M, Baudoin E, Moulin M, Bosenberg M, Graversen JH, Auphan-Anezin N, Moestrup SK, Lawrence T.

J Exp Med. 2019 Aug 2. pii: jem.20182124. doi: 10.1084/jem.20182124. [Epub ahead of print]

PMID:
31375534
2.

Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression.

Goossens P, Rodriguez-Vita J, Etzerodt A, Masse M, Rastoin O, Gouirand V, Ulas T, Papantonopoulou O, Van Eck M, Auphan-Anezin N, Bebien M, Verthuy C, Vu Manh TP, Turner M, Dalod M, Schultze JL, Lawrence T.

Cell Metab. 2019 Jun 4;29(6):1376-1389.e4. doi: 10.1016/j.cmet.2019.02.016. Epub 2019 Mar 28.

PMID:
30930171
3.

Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca2+ signalling and granule mobilization.

Frick M, Mouchacca P, Verdeil G, Hamon Y, Billaudeau C, Buferne M, Fallet M, Auphan-Anezin N, Schmitt-Verhulst AM, Boyer C.

Immunology. 2017 Feb;150(2):199-212. doi: 10.1111/imm.12679. Epub 2016 Nov 2.

4.

Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion.

Giordano M, Henin C, Maurizio J, Imbratta C, Bourdely P, Buferne M, Baitsch L, Vanhille L, Sieweke MH, Speiser DE, Auphan-Anezin N, Schmitt-Verhulst AM, Verdeil G.

EMBO J. 2015 Aug 4;34(15):2042-58. doi: 10.15252/embj.201490786. Epub 2015 Jul 2.

5.

IFNγ producing CD8+ T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas.

Buferne M, Chasson L, Grange M, Mas A, Arnoux F, Bertuzzi M, Naquet P, Leserman L, Schmitt-Verhulst AM, Auphan-Anezin N.

Oncoimmunology. 2015 Mar 6;4(2):e974959. eCollection 2015 Feb.

6.

Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B.

Grange M, Giordano M, Mas A, Roncagalli R, Firaguay G, Nunes JA, Ghysdael J, Schmitt-Verhulst AM, Auphan-Anezin N.

Immunology. 2015 Aug;145(4):543-57. doi: 10.1111/imm.12471. Epub 2015 Jun 15.

7.

In the absence of its cytosolic domain, the CD28 molecule still contributes to T cell activation.

Morin SO, Giroux V, Favre C, Bechah Y, Auphan-Anezin N, Roncagalli R, Mège JL, Olive D, Malissen M, Nunès JA.

Cell Mol Life Sci. 2015 Jul;72(14):2739-48. doi: 10.1007/s00018-015-1873-7. Epub 2015 Mar 1.

8.

Silence STAT3 in the procancer niche… and activate CD8+ T cells to kill premetastatic myeloid intruders.

Auphan-Anezin N, Schmitt-Verhulst AM.

Eur J Immunol. 2015 Jan;45(1):44-8. doi: 10.1002/eji.201445300.

9.

The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Giordano M, Roncagalli R, Bourdely P, Chasson L, Buferne M, Yamasaki S, Beyaert R, van Loo G, Auphan-Anezin N, Schmitt-Verhulst AM, Verdeil G.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11115-20. doi: 10.1073/pnas.1406259111. Epub 2014 Jul 14.

10.

Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-β1 signaling.

Grange M, Verdeil G, Arnoux F, Griffon A, Spicuglia S, Maurizio J, Buferne M, Schmitt-Verhulst AM, Auphan-Anezin N.

J Immunol. 2013 Oct 1;191(7):3712-24. doi: 10.4049/jimmunol.1300319. Epub 2013 Sep 4.

11.

Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?

Auphan-Anezin N, Verdeil G, Grange M, Soudja SM, Wehbe M, Buferne M, Mas A, Schmitt-Verhulst AM.

Pigment Cell Melanoma Res. 2013 Mar;26(2):167-75. doi: 10.1111/pcmr.12056. Epub 2012 Dec 27.

PMID:
23217139
12.

Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma.

Grange M, Buferne M, Verdeil G, Leserman L, Schmitt-Verhulst AM, Auphan-Anezin N.

Cancer Res. 2012 Jan 1;72(1):76-87. doi: 10.1158/0008-5472.CAN-11-2187. Epub 2011 Nov 7.

13.

Disrupted lymph node and splenic stroma in mice with induced inflammatory melanomas is associated with impaired recruitment of T and dendritic cells.

Soudja SM, Henri S, Mello M, Chasson L, Mas A, Wehbe M, Auphan-Anezin N, Leserman L, Van den Eynde B, Schmitt-Verhulst AM.

PLoS One. 2011;6(7):e22639. doi: 10.1371/journal.pone.0022639. Epub 2011 Jul 21.

14.

CD8 T cell help for innate antitumor immunity.

Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F, Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM.

J Immunol. 2007 Nov 15;179(10):6651-62.

15.

[Asymmetric heritage in the daughter].

Auphan-Anezin N.

Med Sci (Paris). 2007 Aug-Sep;23(8-9):685-7. French. No abstract available.

16.

How much can a T-cell antigen receptor adapt to structurally distinct antigenic peptides?

Mazza C, Auphan-Anezin N, Gregoire C, Guimezanes A, Kellenberger C, Roussel A, Kearney A, van der Merwe PA, Schmitt-Verhulst AM, Malissen B.

EMBO J. 2007 Apr 4;26(7):1972-83. Epub 2007 Mar 15.

17.

[The " rendez-vous" of the European immunologists in Paris].

Bonnefoy-Bérard N, Auphan-Anezin N, Sautès-Fridman C.

Med Sci (Paris). 2007 Jan;23(1):105-6. French. No abstract available.

18.

Temporal cross-talk between TCR and STAT signals for CD8 T cell effector differentiation.

Verdeil G, Chaix J, Schmitt-Verhulst AM, Auphan-Anezin N.

Eur J Immunol. 2006 Dec;36(12):3090-100. Review.

19.

Distinct orientation of the alloreactive monoclonal CD8 T cell activation program by three different peptide/MHC complexes.

Auphan-Anezin N, Mazza C, Guimezanes A, Barrett-Wilt GA, Montero-Julian F, Roussel A, Hunt DF, Malissen B, Schmitt-Verhulst AM.

Eur J Immunol. 2006 Jul;36(7):1856-66.

20.

STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors.

Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N.

J Immunol. 2006 Apr 15;176(8):4834-42.

21.

Thymocyte-intrinsic genetic factors influence CD8 T cell lineage commitment and affect selection of a tumor-reactive TCR.

Shanker A, Auphan-Anezin N, Chomez P, Giraudo L, Van den Eynde B, Schmitt-Verhulst AM.

J Immunol. 2004 Apr 15;172(8):5069-77.

22.
23.

Gene profiling approach to establish the molecular bases for partial versus full activation of naïve CD8 T lymphocytes.

Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N.

Ann N Y Acad Sci. 2002 Dec;975:68-76.

PMID:
12538155
24.

Supplemental Content

Loading ...
Support Center